A genomic analysis to determine an individual's response to COVID-19 : Veritas International


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ A genomic analysis to determine an individual's response to COVID-19 : Veritas International
Through the analysis, the researchers can better understand why certain people experience minor or no symptoms and, others suffer severe complications

Genetic factors can determine an individual's possible response to infection, regardless of age and pre-existing conditions. Through the analysis, we can better understand why certain people experience minor or no symptoms and, others suffer severe complications.

The COVID-19 Risk panel can be performed utilizing whole genome or exome sequencing and includes the analysis of complete genes that are associated with severe complications in cases of COVID-19 infection. This information is invaluable in personalizing the individual's COVID-19 treatment.

The analysis looks at three groups of genomic variants, the first one identifies those related to the drugs used to treat COVID-19. The second group studies the factors that cause reversible metabolic or thrombotic complications. The final group studies the genetic factors related to cardiopulmonary complications in the event of an infection with SARS-CoV-2.

Veritas Intercontinental launches its new service analyzing the individual´s response to COVID-19 through whole genome or whole exome sequencing with the objective of personalizing the treatment to avoid medical complications.

A saliva sample is used to perform the analysis so anyone can easily access the service through Veritas or Veritas partners network. Those who already have their genome sequenced through the myGenome by Veritas genomic service can obtain the COVID-19 study by allowing Veritas' to reanalyze their existing information without the need of taking a sample.

From the onset of the pandemic, different scientific advances have allowed the identification of genetic factors related to the most serious forms of COVID-19. These factors are generally related to other conditions that a person has but may not have fully developed. The conditions related to genetic factors can increase the risk of complications from a SARS–CoV–2 infection.

The result of this genetic study can provide a medical professional information to anticipate patient´s management that can possibly reduce the morbidity and mortality of COVID-19 treatment.

The COVID-19 Risk panel analyzes genes with sufficient scientific evidence and offers precise information on three groups of pathologies. The first group identifies those related to the drugs used to treat the disease. The second group studies the factors that cause reversible metabolic or thrombotic crises. The third group studies the genetic factors related to diseases that cause cardiopulmonary complications.

According to Dr Luis Izquierdo, a clinical geneticist and the Chief Medical Officer of Veritas Intercontinental, genetic factors are decisive to understand the different responses that we are witnessing in patients with similar characteristics. "This test - he indicates- is very important because people with pathogenic variants in these genes have a higher risk of complications and this information allows a medical specialist to personalize the treatment in case of COVID-19 infection. For example, carriers of pathogenic variants related to long-QT syndrome may present cardiac arrhythmias for the first time after taking drugs to treat COVID-19 ".

The COVID-19 Risk analysis for myGenome patients can be purchased as a stand-alone service or as part of the Veritas new annual subscription model called Genome Life. Genome Life is a service that provides on-going updates utilizing a myGenome client's already sequenced data. The service offers the possibility to access Veritas Advanced Genomic Services team by providing clients with an annual genetic counseling session, free assessment of additional studies and access to the "Talk to the Experts" genetic support service where patients can send their enquiries about how to maximize the full benefits of their genetic information.

Tags : #VeritasInternational #LatestNewsonVeritasInternational27thNov #LatestPharmaNews27thNov #LatestPharmaResearchonCOVIDInfection27thNov #COVID-19Pandemic #ThromboticComplications #GeneticFactor

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026